BioPartnering Europe 2005 Exhibitor Profiles
October 6, 2005
BioPartnering Europe 2005 takes place 09 – 11 October at Queen Elizabeth II Conference Centre in London, United Kingdom. For in-depth information about the event visit http://www.techvision.com/bpe/#.
Below are profiles from BioPartnering Europe 2005 exhibitors; breaking news releases are available at http://www.tradeshownews.com, Business Wire’s trade show, conference, and event news resource.
Business Wire is the official news wire service for BioPartnering Europe 2005.
Company: Ambit Biosciences Corporation Booth/Stand: Group 4, Booth 20 Media Contact: Rachel Lipsitz Phone: 858-527-3483 E-mail: Rlipsitz@irpr.com Web: www.ambitbio.com With unprecedented speed and efficiency, Ambit’s proprietary kinase platform, KinomeScan, identifies and quantifies binding interactions between small molecules and human proteins. KinomeScan has been validated through partnerships with Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer and Roche as well as articles in PNAS and Nature Biotechnology. Ambit utilized KinomeScan to develop kinase inhibitors for the treatment of cancer and plans to initiate clinical trials in 2006. Ambit has raised a total of $51 million from investors including Perseus-Soros Biopharmaceutical Fund, Forward Ventures, Roche, Avalon Ventures, MDS Capital, Genechem and GIMV NV. Company: Arrow Therapeutics Ltd Booth/Stand: Open House Presenter: Group 4, Booth 14 (Tues 11th Oct, 1:30-4pm) Media Contact: Ken Powell Investor Relations Contact: Annie Clayton Phone: +44 (0)20 7015 1000 E-mail: aclayton@arrowt.co.uk Web: www.arrowt.co.uk Founded in 1998, Arrow Therapeutics is a privately owned pharmaceutical company based in central London. Our research is focused exclusively on the discovery and development of anti-infective therapeutics. We specialise in small molecule drugs with novel mechanisms of action that will address the urgent unmet medical needs in the antiviral and antibacterial fields. Our in-house research efforts have resulted in compounds against Respiratory Syncytial Virus and Hepatitis C in addition to novel antibiotics. With our research approach well established we are now stepping up our development activities. The leading RSV compound completed Phase I in June 2004 and Phase IIa trials began in the second half of 2004. Our lead Hepatitis C compound is planned to enter clinical trials during 2006. Novel antibiotic compounds are currently at lead optimisation stage. Company: Curalogic A/S Booth/Stand: Emerging Company Presentation, Monday 3:45 pm Media Contact: Peter Moldt, CEO Phone: +45 2625 0422 E-mail: pmo@curalogic A/S Web: www.curalogic.com Curalogic is developing novel oral immunotherapy products by applying its proprietary oral drug delivery technologies for the treatment of allergies and diseases. The allergy market was in 2004 greater than USD 10 Billion. Curalogic has three open US INDs. The lead program is development of an oral vaccine for the treatment of ragweed allergy which is entering phase III. Allergy immunotherapy has been documented to give a 30-40% reduction in allergy symptoms over self-administered antihistamine. In comparison, antihistamines provide only a modest approximately 15% reduction in allergy symptoms over placebo. Furthermore, immunotherapy in general has been shown to be curative. Company: CyGenics Booth/Stand: 23 Ticker Symbol & Exchange: CYN ASX Media Contact: Ronald Hee Phone: +65 90619098 E-mail: ronald.hee@cygenics.com Web: www.cygenics.com CyGenics is a cell therapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates four subsidiaries: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in Boston, USA, and CytoVations (new product development) based in New Jersey, USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com. Company: Emergent BioSolutions Limited Booth/Stand: Booth 7 (Group 3) Media Contact: Kim Root Investor Relations Contact: Jonathan Pockson Phone: +44 (0)118 944 3300 E-mail: busdev@ebse.com Web: http://www.ebse.com Emergent BioSolutions’ business is focused on two main areas: biodefence and commercial products. The company has assembled a highly capable team with broad experience of pharmaceutical development gained within different product and commercial environments. EBS will actively manage its portfolio of clinical assets to exploit the opportunities afforded by project BioShield, commercial vaccines and immunotherapeutics. The company will invest internally in those programs where it can lever its skills and expertise to best effect and retain value for the company. At the appropriate stage, it will also seek partnerships with organizations that are able to bring unique assets and capabilities to the collaboration, which will maximize the probability of early commercial launch and success. Company: Enigma Diagnostics Ltd Booth/Stand: 720 Media Contact: Dr Ian George Investor Relations Contact: Dr John Thornback Phone: +44 (0) 1980 590134 E-mail: ian.george@enigmadiagnostics.ocm Web: www.enigmadiagnostics.com Enigma Diagnostics is on a mission to take molecular testing out of the laboratory. Enigma’s portable automatic platform has the accuracy and sensitivity of laboratory based instruments and, combining all procedures in an integrated package, provides a result from raw sample in about 20 minutes. This platform has many potential markets and Enigma is developing a focused portfolio of products for high growth market opportunities in veterinary testing and point of care clinical diagnostics. Company: ERGOMED GROUP Booth/Stand: 24; Monday 2:30-5:00 Media Contact: Klemens Schuette Phone: +49 (0)69 9511740 E-mail: Klemens.schuette@ergomed-cro.com Web: www.ergomed-cro.com Ergomed presents its new flexible co-development model for biotech companies. The comprehensive model addresses the needs for early stage clinical trials, clinical services and finance. Ergomed, the transatlantic drug development company, offers the full-range of clinical facilities and regulatory experience to efficiently drive compounds through the clinical and approval processes in Europe and the US. Ergomed provides the full range of drug development services, including: trial design and strategy, site management, project management, monitoring, pharmacovigilance, quality assurance, data management and regulatory strategies. The Phase I Unit provides access to special patient populations, including: oncology; neurology; hepatic; and renal impaired patients. Company: Evolva Media Contact: info@evolva.com Investor Relations Contact: busdev@evolva.com Phone: +41 61 485 2000 Web: www.evolva.com Evolva is a drug discovery company bringing a new paradigm in that field. Our technology, Watchmaker(R), combines the exploration of uncharted chemical space with a unique evolution-based process leading to the discovery and optimization of small chemical molecules for therapeutic targets. For diabetes, we have rapidly evolved a new class of partial PPAR gamma agonists with a specific co-activator recruitment profile, for one, they do not induce adipocyte differentiation. We are also active in oncology where we evolve small molecules to disrupt Protein:Protein interaction. We are presenting at BPE: Monday, October 10, 12:15-12:29 — Whittle Room, 3rd floor QEII Conference Centre. www.evolva.com Company: Evotec Booth/Stand: 8G56 Ticker Symbol & Exchange: EVT, Frankfurt Stock Exchange, Prime Standard Media Contact: Anne Hennecke Phone: 00 49 40 560 81 0 E-mail: info@evotec.com Web: www.evotec.com Your fully integrated drug discovery and development service provider of choice. Through an unmatched range of integrated scientific capabilities, innovative technology platforms and disease orientated research expertise, Evotec has grown to become a market leading solution provider to pharmaceutical and biotechnology companies globally. We discover and develop novel pharmaceuticals through both service partnerships and investment into a CNS discovery programme. Our skills and expertise in biology, screening and chemistry enable us to generate value by accelerating the discovery and development process, managing risk efficiently, thereby reducing the time and cost of bringing new drugs to the market for our partners. Company: ImaRx Therapeutics, Inc. Booth/Stand: Group 4 Booth 14 Media Contact: Brad Zakes, VP, Business Development Investor Relations Contact: Greg Cobb, CFO Phone: 520-770-1259 E-mail: imarx@imarx.com Web: www.imarx.com ImaRx Therapeutics develops targeted, NanoInvasive(TM) solutions for cardiovascular disease. As innovators in the field, ImaRx has developed late-stage NanoInvasive therapies that provide localized, highly targeted treatments that are significantly less invasive than currently available alternatives. ImaRx’s lead product candidate is a Phase II therapeutic for stroke that extends the treatment window, thereby increasing the overall patient population able to be treated. ImaRx has already achieved commercial success with the development of the world’s best selling nanobubble. The company is strategically poised for growth through the acquisition of two phase III thrombolytic compounds and the initiation of the first ever NanoInvasive trials, which already show promising clinical results in cardiovascular disease. Company: Immatics biotechnologies GmbH Media Contact: Niels Emmerich Investor Relations Contact: Joerg Scheidle Phone: +49 7071 565125-0 E-mail: emmerich@immatics.com, scheidle@immatics.com Web: www.immatics.com immatics is a biopharmaceutical company dedicated to the development of innovative cancer immunotherapeutics. immatics’ proprietary basis of tumor-associated peptides (TUMAPs) provides a huge opportunity for development of novel anti cancer vaccines. Having shown promising clinical results for first TUMAPs in pilot trials, immatics now enters into clinical development in renal cell carcinoma (RCC) with its first multi-TUMAP product candidate IMA901. With XPRESIDENT(TM), immatics owns a unique technology allowing the identification of thousands of TUMAPs directly from primary tumor tissue. immatics was founded in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen (Hans-Georg Rammensee). Company: Inpharmatica Booth/Stand: Group 3 Tuesday October 11th; 9:45 — 12:15 Media Contact: Tatiana Yablonsky Phone: 0207 074 4600 E-mail: t.yablonsky@inpharmatica.co.uk Web: www.inpharmatica.com Inpharmatica Ltd is a selective drug discovery company applying its expertise in structural dynamics, computational biology, and medicinal chemistry to the identification of quality drug targets, chemical leads, and drug candidates. Our technology thereby reduces attrition in the drug discovery process. These technologies are applied to our own successful discovery program and also made available to partners through an integrated chemogenomics suite. Linking genomic and proteomic space with chemistry thus provides a unique approach to hit identification, lead generation, and drug optimisation for druggable targets. Company: InSymbiosis Media Contact: Mr Marcel Pinchevsky, Chief Operating Officer Investor Relations Contact: Dr Dean Wenham, President and CEO Phone: +1 514-807-9315 E-mail: dwenham@insymbiosis.com Web: www.insymbiosis.com InSymbiosis provides research services to the global biopharmaceutical industry. InSymbiosis’ expertise covers early stage research, drug discovery, lead optimization, pharmaceutical development and clinical development. The InSymbiosis model presents a unique enabling approach to our clients via our value drivers: — Accountability: InSymbiosis plan, design and execute parts or all of your projects. — Flexibility: Utilize our pool of R&D resources only when you need them, keeping costs low. — Cost effectiveness: InSymbiosis allow our international clients to benefit from our cost efficient Canadian location. — Productivity: By combining the above, costs are reduced and schedules compressed resulting in maximal productivity. Company: MaxCyte Inc. Media Contact: Douglas Doerfler, President and CEO Investor Relations Contact: Ronald Holtz, Chief Financial Officer Phone: 301-944-1700 E-mail: info@maxcyte.com Web: www.maxcyte.com MaxCyte is a cell therapeutics company with a pipeline of several drug candidates. Programs in development are based on MaxCyte’s platform technology which breaks down the barriers to ex vivo cell loading. MaxCyte’s pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat various diseases with unmet needs. The company also offers its unparalleled, customizable flow based cell loading technology to partners who are developing cell therapies and gene therapies. Partners are currently developing therapeutics for pulmonary and cardiovascular diseases, infectious diseases, cancer, and in regenerative medicine. Company: MedPharm Ltd Booth/Stand: Open-House Presentation Nb 15 Monday, October 10 2:30-5:00 Phone: +44 (0) 16 0881 9267 E-mail: busdev@medpharm.co.uk Web: www.medpharm.co.uk MedPharm is a drug delivery and contract service company committed to the creation and development of novel systems, particularly for topical (skin, nail, mucous membranes) and airway drug formulations. Projects range from simple feasibility tests, dosage design and optimization through to preparation of GMP clinical supplies for Phase I/II trials with guaranteed smooth technology transfer to manufacturing sites. MedPharm has been directly involved in the development of four products currently on the market in the EU and/or US. In parallel to its services, MedPharm invests in its own IP in novel drug delivery technologies which can be licensed to clients. Company: MERISTEM Therapeutics Booth/Stand: OPEN-HOUSE presentation Tuesday October 11th group 3 no. 24 9:45AM-12:15AM And Booth in CORDIA exhibition 940 Phone: 33 4 73 98 68 10 E-mail: meristem@meristem-therapeutics.com Web: meristem-therapeutics.com MERISTEM(R) Therapeutics is a European biotechnology company and leader in recombinant protein production in corn and tobacco. The know-how of the company extends from the cloning of genes coding the protein of interest to the purification of active substance at pharmaceutical grade. Our lead product is MERISPASE(R), a gastric lipase used in the treatment of Exocrine Pancreatic Insufficiency, in particular for Cystic Fibrosis and Chronic Pancreatitis patients. This product is ready for co-development. Our platform allows for the production of a wide range of complex proteins (e.g. antibodies for cancer treatments, collagen, human allergens, lactoferrin). Our partners can benefit from our platform with increased production flexibility, lower production costs, and low capital investment. Company: OctoPlus Booth/Stand: Booth 13, Tuesday 13.30 — 16.00 hrs Media Contact: Joost Holthuis, CEO Investor Relations Contact: Hans Pauli, CFO Phone: +31-71-5244044 E-mail: info@octoplus.nl Web: www.octoplus.nl OctoPlus is a clinical-stage, product-oriented drug delivery company focused on parenteral controlled release. Products in development include amongst others controlled release formulations of recombinant human alfa interferon and growth hormone. OctoPlus is also an internationally established provider of pharmaceutical development services and cGMP manufacturing to biotech and pharma companies worldwide. Recent news: on September 26th, OctoPlus and SingVax announced their collaboration to develop a single-shot Japanese encephalitis (JE) vaccine. Existing JE vaccines typically require two or three doses. By creating a single-shot JE vaccine the companies aim to achieve increased patient compliance and greater efficacy of the vaccine. Company: Optimata Ltd. Media Contact: Mr. Guy Malchi Phone: +972 3 751 9226 E-mail: guy@optimata.com Web: www.optimata.com Active since 2000, privately owned, interdisciplinary science-based, Optimata Ltd. develops and markets computerized products — Virtual Patient engines — for accelerating drug development and optimizing patient treatment. Using Bio-Mathematics to develop a predictive Bio-simulation software toolkit, these products provide a comprehensive drug development solution, from the pre-clinical phase through treatment personalization. They thoroughly unfold drug/patient dynamic interactions, enabling drug developers to perform rapid virtual clinical trials and to forecast optimal drug treatment. This allows: — Comprehensive toxicity and efficacy profile prediction — Optimizing fit between drug protocols and sub populations — Drug indication selection / expansion — Drug salvage and drug repurposing Company: PAION Booth/Stand: Group 2, Booth 21 Ticker Symbol & Exchange: PA8 Media Contact: Dr. Peer Nils Schroder Phone: +49-241-4453-152 E-mail: pn.schroeder@paion.de Web: www.paion.de PAION, a biopharmaceutical company based in Aachen, Germany, aims to become a leader in developing and commercialising innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. PAION intends to build an integrated drug portfolio by exploiting its expertise in identifying compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process. PAION’s lead product Desmoteplase for the treatment of acute ischaemic stroke is currently in Phase III. During the first half-year 2005, PAION employed on average 59 people. Company: Pharmagene Laboratories Ltd Booth/Stand: 21 Ticker Symbol & Exchange: PGN Media Contact: Ronald Openshaw Investor Relations Contact: Financial Dynamics Phone: 01763 211600 E-mail: info@pharmagene.com Web: www.pharmagene.com Pharmagene provides human tissue-based drug discovery services using fully consented human tissue for which it has established, and maintains, one of the most effective tissue supply networks in the world. Pharmagene provides services in human functional pharmacology, biochemical and safety pharmacology and gene/protein profiling in many therapeutic areas. These techniques are used in target validation to evaluate which targets are relevant to human disease, in compound validation to aid prioritisation of pre-clinical candidate compounds prior to entry into the clinic. They can also be used to extract greater value from existing compounds, by identifying possible new indications. Pharmagene announced on 19th Sept 2005, it’s intention to merge with Asterand, a Detroit based Biotech company that specialises in the supply of high quality human tissue and tissue-based services. For more information go to our website www.pharmagene.com. Company: PharmaLinks Booth/Stand: Group 4 booth 22 Media Contact: Anne Muir Phone: +44.141.548.3755 E-mail: info@pharmalinks.org Web: http://www.pharmalinks.org PharmaLinks — helping pharmaceutical and biotechnology companies go from concept to compound by providing flexible solutions to advance drug discovery and development projects. PharmaLinks is based on the expertise and facilities of two Scottish universities — the University of Glasgow and University of Strathclyde. PharmaLinks draws on 1200 biomedical researchers providing access to expertise in most diseases and therapeutic areas (cancer, cardiovascular, neuroscience, inflammation, infection) and key technology areas (synthetic/medicinal chemistry, functional pharmacology, models, formulation/drug delivery and clinical trials), as well as proprietary lead compounds. From early-stage compounds to bespoke discovery programmes, we offer research solutions to advance drug discovery and development. Company: Proteome Sciences plc Booth/Stand: Open House Presentation — Group 4 (Tues Oct 11th, 1.30-4) — Booth 10 Ticker Symbol & Exchange: PRM/LSE Media Contact: James Green — Commercial Director Investor Relations Contact: Christopher Pearce — Chief Executive Phone: +44 (0)1932 865065 E-mail: susan.harris@proteomics.com Web: www.proteomics.com Proteome Sciences, a global leader in applied proteomics, uses high sensitivity proprietary technologies to detect differentially expressed proteins in diseases. The protein biomarkers discovered in body fluids or tissues are validated, developed and commercialised as diagnostic, prognostic or therapeutic products through strategic alliances and out-licensing. Through its unique ProteoSHOP(R) toolkit, Proteome Sciences provides high sensitivity/high throughput proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein sequence tag technologies (PST(R), qPST(TM)& TMT(R)), to major pharma, biotechnology and diagnostic companies, to discover and exploit protein biomarkers. Sensitizer(R) chemical mass tags have been developed separately as a series of stand-alone reagents. Company: RNTECH SAS Booth/Stand: 4 — Tuesday October 11, 10:00 to 12:30 Phone: +33 1 4007 1121 E-mail: mbia@rntech.com Web: www.rntech.com “RNTech” is a leading company in early stage digestive tract cancer diagnostic tools and drugable targets discovery and development supported by an exclusive access to proprietary high standard biological material and clinical data bank combined with original discovery processes backed by state of the art technology platforms. From the origin highest ethical and technical standards are applied. The exclusive collaboration with the “Fundeni Institute” in Bucharest has built an original biological and clinical data bank representing currently 15,000+ samples of biological material. “RNTech” is associated with DNAVision (www.dnavision.be) to perform collaborative and contract research and jointly market products and services. Company: TopoTarget Booth/Stand: Monday 10th Oct 10am-12.30pm, Booth 15 Ticker Symbol & Exchange: TOPO (CSE) Media Contact: Dr Peter Buhl Jensen (CEO) Investor Relations Contact: Hanne Leth Hillman (Director, Investor Relations) Phone: +45 39 17 94 99 E-mail: hlh@topotarget.com Web: www.TopoTarget.com TopoTarget is a fully integrated biopharmaceutical company with operations in Denmark, UK and Germany, dedicated to developing improved therapies for cancer, with a strong focus on cancer patient needs. The company combines an in-depth understanding of the molecular mechanisms of cancer and use of predictive clinical models, with a wide experience in clinical oncology practice. TopoTarget’s pipeline is balanced between niche cancer products which it aims to market itself in Europe, and novel compounds of broad potential application which will be marketed by partners. The pipeline includes eight programmes in clinical trials, the most advanced of which was submitted to EMEA for marketing approval in August 2005. Company: Tranzyme Pharma Booth/Stand: 5 Media Contact: Vincent Parrino (vparrino@tranzyme.com) Investor Relations Contact: Richard Eisenstadt (reisenstadt@tranzyme.com) Phone: (919) 313-4760 E-mail: contact@tranzyme.com Web: www.tranzyme.com Tranzyme Pharma is a leading biopharmaceutical company developing novel orally bioavailable, small molecule therapeutics for the treatment of gastrointestinal (GI) diseases. The Company’s candidate drugs originate from its own discovery pipeline of proprietary compounds with high affinity for validated and druggable targets in the GI tract. Tranzyme is developing mechanism-based therapeutics for post-operative ileus, diabetic gastroparesis, irritable bowel syndrome (diarrhea-type) and functional dyspepsia and is on track to enter the clinic with its first product in the first quarter of 2006. Tranzyme is leveraging its technologies through internal programs and partnerships to drive the discovery and development of new therapeutics. Company: Trigen Holdings AG Booth/Stand: 19 — Open House presenter Tuesday afternoon Media Contact: Ashley Tapp, Head of Corporate Communications Phone: 44 20 7004 2653 E-mail: 44 20 7004 2631 Web: www.trigen.co.uk Trigen Holdings AG is a biopharmaceutical company with operations in London and Munich and a leader in cardiovascular drug discovery and development, focusing on thrombosis and vascular dysfunction. The company’s product pipeline includes TGN 255, TGN 167 and PR-15 (which is expected to enter the clinic later this year). The company also has an extensive portfolio of exciting pre-clinical and discovery stage programmes targeting thrombosis, atherosclerosis and other cardiovascular pathologies. The company benefits from in-house discovery and development expertise in small molecule and protein therapeutics, bringing together existing highly-skilled chemistry and biology teams in the UK and Germany. Trigen also benefits from two established discovery platforms, SIGSCREEN(R) and THROMSCAN(R) which have been applied in collaborations with a number of multinational pharmaceutical companies. Company: TriStar Technology Group, LLC Booth/Stand: 16 Media Contact: Milan Bhagat Phone: 301.896.9442 E-mail: milan@tristar-usa.net Web: www.tristargroup.us TriStar brings the power of high throughput tissue analysis to significantly facilitate and accelerate in situ target discovery and validation. We have one of the world’s largest repositories of human cancer Tissue Micro Arrays (TMAs) and work with leading research based Pharmaceutical companies in three important phases of drug development: (a) Determining the prevalence of target gene alterations in one or several cancer types. (b) Developing predictive methods to identify those patients with the highest likelihood of benefiting from a new therapy. (c) Screening tissues from clinical study patients for subsequent molecular analyses to be able to retrospectively identify predictive molecular markers. Dr. Guido Sauter, Director of the Institute of Pathology at the University of Hamburg, leads our scientific team. Dr Sauter has been working with therapeutic target genes since 1993 when he was the first pathologist to use HER2 FISH probes. Our multi tumor arrays enable the screening of 10 — 50 samples each from 120 human cancers for the expression of novel targets, providing valuable IP for the development of both small molecule as well as antibody therapeutics. TriStar cancer specific arrays have up to 2200 donor specimens supported by raw and tumor-specific survival information. We now offer formalin fixed / frozen tissue arrays, tissue sections, RNA, DNA and Serum for research in the areas of Oncology, CNS, Autoimmune, and Cardiovascular disease. Company: YM BioSciences Inc. Booth/Stand: Group 3, Booth 14 Ticker Symbol & Exchange: AMEX — YMI, TSX — YM, AIM — YMBA Media Contact: James Smith Investor Relations Contact: Carolyn McEwen Phone: 905-629-9761 E-mail: ir@ymbiosciences.com Web: www.ymbiosciences.com YM BioSciences’ lead drug, tesmilifene, is a chemopotentiator that completed enrollment in a 700-patient pivotal PIII trial in metastatic breast cancer. Results from the first PIII trial demonstrated a substantial increase in survival for women treated with the combination of tesmilifene/chemotherapy compared to chemotherapy alone. YM is also developing nimotuzumab, an anti-EGFr humanized monoclonal antibody, and its anti-GnRH, anti-cancer vaccine, Norelin, for which PII data was released. In 05/2005, YM acquired DELEX, a biotechnology company developing AeroLEF, an inhaled formulation of fentanyl, to treat acute pain, which completed a PIIa trial with positive results and a randomized PIIb pain trial has been cleared to start. Company: XOMA (US) LLC Booth/Stand: Group 3, Booth 5 Ticker Symbol & Exchange: XOMA Media Contact: Ellen Martin, Kureczka/Martin Associates Phone: 510-832-2044 E-mail: Emm4@pacbell.net Web: www.xoma.com XOMA is a leader in the discovery, development and manufacturing of therapeutic monoclonal antibodies (mAbs). XOMA’s mAb platform includes leading commercial antibody phage display libraries, hybridoma, Human Engineering(TM) and affinity maturation technologies, and a fully integrated product development infrastructure, including cell line and process development, preclinical and clinical functions, and manufacturing. XOMA’s pipeline includes both proprietary products and collaborative programs. XOMA receives royalties for RAPTIVA(R) marketed in the US by Genentech Inc. and ex-US by Serono SA for the treatment of moderate-to-severe psoriasis. Other strategic collaborators include Aphton Corporation, Chiron Corporation and Lexicon Genetics.
Note to Editors: Business Wire’s PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content to experts, company profiles, email alerts, survey services and other media services.
Note to Event Organizers: Add your trade show, conference, or event to www.tradeshownews.com, Business Wire’s online event calendar. For information, email tradeshow@businesswire.com.